Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
GLP-1 concentrations were elevated in both older groups [GLP-1 area under the curve (AUC)0-120 was 2.8 ± 0.1 in Y-NGT, 3.8 ± 0.5 in O-NGT, and 3.7 ± 0.4 nmol/L∙120 minutes in O-IGT subjects; P < 0.05], whereas GIP secretion was higher in O-NGT than in Y-NGT subjects (GIP AUC0-120 was 4.7 ± 0.3 in Y-NGT, 6.0 ± 0.4 in O-NGT, and 4.8 ± 0.3 nmol/L∙120 minutes in O-IGT subjects; P < 0.05).
|
29672742 |
2018 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, Lhx1<sup>∆Panc</sup> mice exhibit significantly reduced Glp1R, an mRNA encoding the insulinotropic receptor for glucagon-like peptide 1 along with a concomitant dampened Glp1 response and mild glucose intolerance in mice challenged with oral glucose.
|
30620636 |
2019 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Aging is associated with reductions in fasting GLP-1 and GIP, and glucose-stimulated GLP-1, which may predispose to the development of glucose intolerance and type 2 diabetes.
|
31393567 |
2019 |
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
LHGDN |
Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance.
|
17944883 |
2008 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BMI = body mass index; DPP-4 = dipeptidyl peptidase-4; DXA = dual energy X-ray absorptiometry; GIP = glucose-dependent insulinotropic peptide; GLP-1 = glucagon-like peptide-1; HOMA-B = homeostasis model assessment for beta-cell function; HOMA-IR = homeostasis model assessment of insulin resistance; IAI = insulin action index; IGT = impaired glucose tolerance; IR = insulin resistance; MBCI = modified beta-cell function index; OGTT = oral glucose tolerance test; QUICKI = quantitative insulin sensitivity check index; PCOS = polycystic ovary syndrome; SHBG = sex hormone-binding globulin; T2D = type 2 diabetes.
|
29144805 |
2018 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance.
|
29466430 |
2018 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Drug-induced activation of this inhibitory designer receptor almost completely shut off glucagon secretion in vivo, resulting in significantly impaired insulin secretion, hyperglycemia, and glucose intolerance.
|
31012868 |
2019 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Ex9 impaired glucose tolerance in wild-type mice but had no impact on Gcg-null or GLP-1R KO mice, suggesting that Ex9 is a true and specific GLP-1R antagonist.
|
28325479 |
2017 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hence, enhancing endogenous GLP-1 secretion by certain materials could be a potential target for prevention of glucose intolerance.
|
31352909 |
2019 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
|
16125528 |
2005 |
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Improvement of reduced grooming behavior and normalization in reduced plasma insulin levels were seen only in 5M+2M Tg2576 mice while in 10M+2M Tg2576 mice oral galactose induced metabolic exacerbation at the level of plasma insulin, GLP-1 homeostasis and glucose intolerance, and additionally increased hippocampal sAβ1-42 level, decreased IR expression and increased GSK-3β activity.
|
30571958 |
2019 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition to impairment of glucose-induced insulin secretion, impaired glucagon-like peptide (GLP)1-induced insulin secretion has been identified to be present in subjects with diabetes and impaired glucose tolerance, but little is known about its fundamental mechanisms.
|
22928568 |
2012 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Increasing secretion and production of glucagon-like peptide-1 (GLP-1) by continuous ingestion of certain food components has been expected to prevent glucose intolerance and obesity.
|
28161724 |
2018 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide [GIP]) may play a role in the development of glucose intolerance and hyperglycemia in patients with hyperthyroidism.
|
28452237 |
2017 |
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study.
|
18080106 |
2008 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results indicate that high-glucose load leads to glucose intolerance with insulin resistance through impairment of GLP-1 secretion, increase of blood glucose levels via activating TLR4 and increasing levels of IL-6 and TNF-α in mice.
|
31138952 |
2019 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Ovx mice exhibited impaired glucose tolerance during oral glucose tolerance tests (OGTT), which was associated with decreased GLP-1 intestinal and pancreatic secretion and content, an effect that was reversed by estradiol (E2) treatment.
|
29618657 |
2018 |
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The effect of incretin hormones to increase insulin release is reduced in ESRD which together with elevated glucagon levels could contribute to the high prevalence of IGT among ESRD patients.
|
31608934 |
2020 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The increment of postprandial GLP-1 and insulinsecretion may have a role in normalizing postprandial glycaemia and slowing the establishment of glucose intolerance.
|
30878816 |
2019 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The potent and selective GLP-1-releasing effect of allulose holds promise for the prevention and treatment of glucose intolerance through promoting endogenous GLP-1 secretion.
|
29402406 |
2018 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance.
|
28946907 |
2017 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The results reveal that by potentiating KATP channels, CFTR acts as a glucose-sensing negative regulator of glucagon secretion in α cells, a defect of which may contribute to glucose intolerance in CF and other types of diabetes.
|
28977595 |
2017 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
There was a weak relationship between the iAUC<sub>0-240 min</sub> for GIP and GLP-1 in the combined (r = 0.23, P = 0.015) and in the IGT (r = 0.34, P = 0.01), but not in the NGT (r = 0.15, P = 0.14) group.
|
31848710 |
2019 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that GLP-1 normalizes the obesity-induced compensatory increase in β-cell mass and glucose intolerance through a neuronal relay system consisting of hepatic afferent nerves, the hypothalamus, and pancreatic efferent nerves.
|
28717164 |
2017 |
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, the postprandial GLP-1 response is not necessarily decreased but rather enhanced during obesity development, which is likely to play a protective role against glucose intolerance.
|
31636017 |
2020 |